These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 4217465)

  • 1. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 2. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 3. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 8. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 9. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 13. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 16. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 19. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.